

CURRICULUM VITAE
Maximilian Stahl, MD

Version date: 04/01/2025

Proposed for: Initial appointment as Assistant Professor of Medicine (Hematology)

Term: 04/01/2025-06/01/2027

School: Yale School of Medicine

Education:

08/2006-05/2013 MD, Hannover Medical School, Hannover, Germany

Career/Academic Appointments:

06/2013-06/2014 Research Fellow, Yale Stem Cell Center, Yale University, New Haven, CT

07/2014-06/2015 Intern, Internal Medicine, Yale New Haven Hospital, New Haven, CT

07/2015-06/2017 Resident, Internal Medicine, Yale New Haven Hospital, New Haven, CT

07/2017-06/2018 Chief Resident, Internal Medicine, Yale New Haven Hospital, New Haven, CT

07/2018-06/2021 Fellow in Medical Oncology & Hematology, Memorial-Sloan Kettering Cancer Center, New York, NY

07/2019-06/2021 Research Fellow, The Rockefeller University, New York, NY

07/2021-10/2023 Instructor, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Associate Physician Brigham and Women's Hospital, Boston, MA

11/2024-03/2025 Assistant Professor, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Associate Physician Brigham and Women's Hospital, Boston, MA

04/2025-current Assistant Professor, Yale Cancer Center and Yale School of Medicine, New Haven, CT

Administrative Positions:

2017-2018 Chief Resident, Internal Medicine, Yale New Haven Hospital, New Haven, CT

2020-2021 Chief Fellow in Hematology, Memorial-Sloan Kettering Cancer Center, New York, NY

2022-2024 Co-Director, Leukemia Clinical Data Repository Dana-Farber Cancer Institute, Boston, MA

2025-present Director of the Clinical Myeloid Malignancy and Acute Leukemia Program, Yale Cancer Center, Yale School of Medicine, New Haven, CT

2025-present Director of the Myeloid Malignancy and Acute Leukemia Clinical Research Program, Yale Cancer Center, Yale School of Medicine, New Haven, CT

2025-present Chief of the Duffy Hematology Firm, Yale New Haven Hospital, New Haven, CT

Board Certification:

2017-2027 American Board of Internal Medicine

2021-2031 American Board of Internal Medicine – Medical Oncology

2021-2031 American Board of Internal Medicine – Hematology

Professional Honors & Recognition:

International/National/Regional

2006-2013 Full Academic Scholarship, German National Academic Scholarship Foundation (Studienstiftung des Deutschen Volkes)

2016 Abstract achievement award Annual Meeting of the American Society of Hematology

2017 Abstract achievement award Annual Meeting of the American Society of Hematology

2017 HONORS award American Society of Hematology

2020 Abstract achievement award Annual Meeting of the American Society of Hematology

University

2016 Samuel D. Kuslan Award, Yale Internal Medicine Program, Yale School of Medicine
2017 Stephen R. Shell Award, Yale Internal Medicine Program, Yale School of Medicine

Grant/Clinical Trials History:

Current Grants

N/A

Current Clinical Trials

N/A

Past Grants

Agency: Cycle for Survival Foundation
ID#: GC240982
Title: Metabolic Mechanisms of Response and Resistance to Novel Therapies in Acute Myeloid Leukemia (AML)
PI: Ed Reznik, PhD
Role on Project: Co-Investigator
Percent effort: 10%
Total costs: \$396,734 (includes indirects)
Project period: 9/01/2019 – 8/31/2020

Agency: National Cancer Institute
ID#: P01 Grant, 2P01CA17198306A1
Title: Targeted Sphingolipid Metabolism for Treatment of AML
PI: Mark Kester, PhD
Role on Project: Co-Investigator
Percent effort: 2.5%
Total costs: \$603,354 (includes \$174,857 indirects)
Project period: 05/01/2020 – 04/30/2021

Agency: Leukemia and Lymphoma Society
ID#: Translational Research Program (DFCI 23-534)
Title: Combination of cytokine induced memory-like (CIML) NK cells with venetoclax to eradicate measurable residual disease (MRD) in AML
PI: Maximilian Stahl, MD
Role on Project: Principal Investigator
Percent effort: 4.5%
Total costs: \$750,000 (includes indirects)
Project period: 12/01/2023 – 04/01/2025

Agency: Break Through Cancer Foundation
ID#: Break Through Cancer Foundation Grant (DFCI 23-658)
Title: A Multi-Site Break Through Cancer Pilot Study testing the feasibility and safety of therapeutic intervention for patients with high-risk clonal cytopenia of undetermined significance (CCUS)
PI: Benjamin Ebert, MD PhD
Role on Project: Co-Investigator
Percent effort: 6.0%
Total costs: \$1,164,918 (includes indirects)
Project period: 05/01/2020 – 04/01/2025

Past Clinical Trials

Agency: Shattuck Labs, Inc
ID#: NCT05275439 (DFCI 22-413)
Title: An Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPa-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
PI: Maximilian Stahl, MD
Percent effort: N/A
Total costs: N/A
Project period: 2022 – 2024

Agency: Novartis Pharmaceuticals
ID#: NCT05552469 (DFCI 23-066)
Title: A Phase 1b, Open Label, Multi-Center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients with Myeloid Diseases
PI: Maximilian Stahl, MD
Percent effort: N/A
Total costs: \$280,000
Project period: 2023 – 2025

Agency: Massachusetts General Hospital
ID#: NCT04801797 (DFCI 21-113)
Title: A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults With Acute Myeloid Leukemia
PI: Amir Fathi, MD
Role: Sub-Investigator
Percent effort: N/A
Total costs: \$25,346
Project period: 2024 – 2025

Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated with Yale:

International/National

1. “Experts Under the Microscope: Evaluating the Role of Maintenance Therapy in Long-Term Management of AML.” New Orleans, LA, 2022.
2. “Career path in and outside of academic oncology.” Fellow and Junior Faculty Career Development Workshop in MDS Research, International Working Group for MDS (iwMDS) Meeting, Miami, FL, 2022.
3. “Should We Give HMA before allo-SCT for HR-MDS with 5-9% Blasts?” 1st World Congress on Controversies in MDS and AML (COMydAL), Paris, France, 2022.
4. “How Do I Assess Risk in Myelodysplastic Syndromes?” First Affiliated Hospital Sun Yat-sen University, Guangzhou, Guangdong, China, 2023.
5. “Should We Give HMA as Cyto-reduction prior to allo-SCT for High Risk MDS? / Invited lecture?” 4th King Faisal Specialist Hospital & Research Centre (KFSHRC) Jeddah Transplantation and Cellular Therapy Annual Conference, Riyadh, Saudi Arabia, 2022.
6. “Individualized Management of Acute Myeloid Leukemia: Guidance for the Community Multidisciplinary Team.” Clinical Care Options (CCO), Reston, VA, 2023.
7. “Value of MRD Assessment with Intensive Chemotherapy Regimens in AML: Open Questions and Controversies.” International Working Group for Acute Leukemia (iwAL) Meeting, San Diego, CA, 2023.
8. “Venetoclax Combination Therapy as a Bridge to HSCT in Elderly or Unfit AML.” 7th International Congress of Bone Marrow Transplantation (ICBMT) and the 28th Annual Congress of the Korean Society of BMT (KSBMT), Busan, South Korea, 2023.

9. “Preventing Progression: A Multi-Site Break Through Cancer Pilot Study Testing the Feasibility and Safety of Therapeutic Intervention for Patients with High-Risk Clonal Cytopenia of Undetermined Significance (CCUS).” Breakthrough Cancer Symposium, Kiawah Island, SC, 2023.
10. “Myelodysplastic Syndromes – Clinical and Epidemiological: Treatments and Outcome Predictions in High Risk MDS Session.” Moderator, ASH Annual Meeting and Exposition, San Diego, CA, 2023.
11. “Pathogenesis of TP53-Mutated Myeloid Malignancies.” Educational Session on TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes, ASCO Annual Meeting, Chicago, IL, 2024.
12. “Luspatercept is the New Standard of Care as First Line Therapy for LR-MDS?” MPN-MDS US Focus Meeting, La Jolla, CA, 2024.
13. “Individualizing Therapy in Low-Risk MDS: New Evidence and Options for Your Patients.” Free Oncology Symposia in Conjunction with the 2024 ASCO Annual Meeting, Chicago, IL, 2024.
14. “Post-ASH 2023 MDS Highlights.” Moderator, The Video Journal of Hematology and Hematological Oncology (VJHemOnc) Webinar, Oxford, England (virtual), 2024.
15. “Oral Decitabine as an Intervention Strategy for High-Risk Clonal Cytopenia of Undetermined Significance (CCUS).” Intercepting Blood Cancers (IBC) Workshop, Lisbon, Portugal, 2024.
16. “Novel Therapeutic Options for Patients with Myelodysplastic Syndromes.” Romanian Society of Hematology Focus Meeting on MDS, Cluj, Romania, 2024.
17. “Novel Agents in MDS being Explored from ASH 2023 and Beyond.” VJ Hem Onc (The Video Journal of Hematology and Hematologic Oncology), Oxford, England (virtual), 2024.
18. “Practical Management of Anemia in LR-MDS.” VJ Hem Onc (The Video Journal of Hematology and Hematologic Oncology), Oxford, England (virtual), 2024.
19. “What to Do with TP53 Mutated Higher Risk MDS/AML?” Joint COMyDAL, COLYM, MPNCo&D and 7th Annual Meeting of the International Academy for Clinical Hematology (IACH), Paris, France, 2024.
20. “How does venetoclax fit in the management of higher risk MDS?” Joint COMyDAL, COLYM, MPNCo&D and 7th Annual Meeting of the International Academy for Clinical Hematology (IACH), Paris, France, 2024.
21. “Role and Optimal Maintenance Strategies in AML Patients not Going to ASCT.” International Working Group for Acute Leukemia (iwAL) Meeting, Phoenix, AZ, 2024.

Regional

1. “Cancer Metabolism.” MSK Cancer Biology Seminar Series, Department of Medicine, Memorial-Sloan Kettering Cancer Center, New York, NY, 2018.
2. “Thinking like an Oncologist-Acute Myeloid Leukemia.” MSK Fellows Seminar Series, Department of Medicine, Memorial-Sloan Kettering Cancer Center, New York, NY, 2018.
3. “Diagnostic and Prognostic Considerations in MDS.” Lecture series for Clinical research staff, Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, 2022.
4. “Critical Appraisal of the AGILE trial in IDH1 Mutated Acute Myeloid Leukemia.” Brigham and Women’s Hospital Internal Medicine Noon conference, Boston, MA, 2022.
5. “Introduction of MDS to Clinical Research Team.” Lecture series for Clinical research staff, Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, 2022.
6. “Primer on Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia.” Brigham and Women’s Faulkner Hospital Internal Medicine Noon conference, Boston, MA, 2022.
7. “Primer to AML and MDS: Current Landscape and Unmet Clinical Need.” Curis Oncology, Lexington, MA, 2022.
8. “Primer on Acute Myeloid Leukemia.” Brigham and Women’s Faulkner Hospital Internal Medicine Noon conference, Boston, MA, 2022.

9. “Evidence-Based Guidance on Current Paradigms and New Therapeutic Approaches in AML.” Gather-ed Webinar, New York, NY, 2022.
10. “High Risk AML” Lecture series for Clinical research staff, Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, 2022.
11. “Risk Assessment in MDS”. Department of Medicine, Massachusetts General Hospital (MGH), Boston, MA, 2022.
12. “Insights and Impact: Using Collaborative Small Groups to Understand and Address Practice Gaps in the Management of MDS.” Gather-ed Webinar, New York, NY, 2022.
13. “Novel Treatments in Acute Leukemia.” Brigham and Women’s Faulkner Hospital Internal Medicine Noon conference, Boston, MA, 2023.
14. “What the Internal Medicine Resident Needs to Know about Acute Leukemia.” Brigham and Women’s Faulkner Hospital Internal Medicine Noon conference, Boston, MA, 2023.
15. “Best of ASH: Leukemia”, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 2023.
16. “What is New in Myelodysplastic Syndromes for Clinical Research Coordinators?” Lecture series for Clinical research staff, Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, 2023.
17. “Updates about Risk Stratification and Treatment in MDS.” Dana-Farber Brigham Cancer Center (DF/BCC) in Clinical Affiliation with South Shore Hospital, South Weymouth, MA
18. “Diagnosis and Management of Acute Promyelocytic Leukemia.” Brigham and Women’s Faulkner Hospital Internal Medicine Noon conference, Boston, MA, 2024.
19. “How to Manage Leukemia in the First 48 Hours of Presentation.” Brigham and Women’s Faulkner Hospital Internal Medicine Noon conference, Boston, MA, 2024.
20. “New Therapeutic Options in AML.” Grand Rounds, Northern Light Cancer Care, Brewer, ME, 2024.
21. “Updates on Acute Myeloid Leukemia.” 8th Annual OncLive Medical Crossfire: Hematologic Malignancies, New York, NY, 2024.

Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated with Yale:

International/National

1. **Stahl M**, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM. The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. ASH 2016 Annual Meeting, San Diego, CA, December 2016 (Oral presentation).
2. **Stahl M**, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ, Zeidan AM. Long-Term Survival of Older Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agent Therapy: A Large Population-Based Analysis. ASH 2017 Annual Meeting, Atlanta, GA, December 2017 (Oral presentation).
3. **Stahl M**, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM. The Impact of the Administration Schedule and Mutational Profile on Outcomes of Patients with Relapsed and Refractory Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Large, International, Multi-Center Analysis. ASH 2017 Annual Meeting, Atlanta, GA, December 2017 (Oral presentation).
4. **Stahl M**, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM. The Use of Immunosuppressive Therapy

- (IST) in Patients with Myelodysplastic Syndromes (MDS): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. ASH 2017 Annual Meeting, Atlanta, GA, December 2017 (Oral presentation).
5. **Stahl M**, Derkach A, Farnoud N, Bewersdorf JP, Robinson T, Famulare C, Cho C, Devlin S, Menghrajani K, Patel MA, Cai SF, Miles LA, Bowman RL, Geyer MB, Dunbar A, Epstein-Peterson ZD, McGovern E, Schulman J, Glass JL, Taylor J, Viny AD, Stein EM, Getta B, Arcila ME, Gao Q, Barker J, Shaffer BC, Papadopoulos EB, Gyurkocza B, Perales MA, Abdel-Wahab O, Levine RL, Giralt SA, Zhang Y, Xiao W, Pai N, Papaemmanuil E, Tallman MS, Roshal M, Goldberg AD. Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. ASH 2020 Annual Meeting, San Diego, CA, December 2020 (Oral presentation).
 6. Desai P, Hicks LK, Tucker E, Anderson KC, Tallman MS, Sekeres MS, Roboz GJ, Sehn LH, Goldberg AD, Redd, RA, Thompson JC, Wood, WA, Neuberg DS, **Stahl M**, Narendra V, Radhakrishnan V. Clinical Predictors of Outcome in Adult Patients with Acute Leukemias and Myelodysplastic Syndrome and COVID-19 Infection: Report from the American Society of Hematology Research Collaborative (ASH RC) Data Hub. ASH 2021 Annual Meeting, Atlanta, GA, 2021 (Poster presentation).
 7. Grenet G, Desai P, Roboz GJ, Sweet K, Dinner S, Jain AG, Lee S, Ritchie E, Goldberg AD, Kaner, JD, Samuel MB, Christos PJ, Ma X, Ball B, McKinnell Z, **Stahl M**, Numan Y, Famulare C, Waksal J, Burkart M. Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia. ASH 2021 Annual Meeting, Atlanta, GA, 2021 (Poster presentation).
 8. Hicks LK, Redd R, Anderson K, Desai P, Dolan B, Goldberg AD, Narendra V, Neuberg D, Radhakrishnan VS, Sehn LH, Sekeres MA, **Stahl M**, Thompson C, Wood WA. Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology. ASH 2021 Annual Meeting, Atlanta, GA, 2021 (Poster presentation).
 9. Lanino L, Ball S, Bewersdorf J, Marchetti M, Maggioni G, Travaglino E, Al Ali N, Fenaux P, Platzbecker U, Santini V, Díez Campelo M, Singh A, Jain A, Aguirre LE, Tinsley S, Schwabkey Z, Chan O, Xie Z, Brunner A, Kuykendall A, Bennett J, Buckstein R, Bejar R, Carraway H, DeZern A, Griffiths EA, Halene S, Hasserjian R, Lancet J, List A, Loghavi S, Odenike O, Padron E, Patnaik M, Roboz G, **Stahl M**, Sekeres M, Steensma D, Savona M, Taylor J, Xu M, Sweet K, Sallman D, Nimer S, Hourigan C, Wei A, Sauta E, Borate U, Sanz G, Efficace F, Gore S, Kon Kim T, Daver N, Garcia-Manero G, Orfao A, Rozman M, Wang S, Foucar K, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrabener M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht A, Ades L, Komrokji R, Zeidan A, Giovanni Della Porta M. Data-Driven Harmonization of 2022 WHO and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS). ASH 2023 Annual Meeting, San Diego, CA, 2023 (Oral Presentation).
 10. Osei MA, Merz LE, Chien K, Hammond D, Coleman Lindsley R, Luskin MR, **Stahl M**, How J, Wazir M, Marneth A, Shimmony S, Mullaly A, DeAngelo DJ, Garcia-Manero G, Achebe M, Ebert B, Weeks LD. Myeloid Neoplasia in Patients with Hereditary Hemoglobinopathies and Hemolytic Anemias (HHAs). ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).
 11. Stempel JM, Li A, Pine A, Bewersdorf JP, **Stahl M**, Podoltsev N, Mendez L, Shallis RM, Lee AI, Michaelis L, Zeidan AM. Evaluating Inpatient Care Team Models in Hematology and Oncology Fellowship Programs in the United States. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).
 12. Luskin MR, Shimmony S, Keating J, Stock W, Hock H, Garcia JS, **Stahl M**, Galinsky I, Leonard R, Weiner H, Flamand Y, Neuberg DS, Stone RM, Letai AG, Winer ES, Konopleva M, Jain N, DeAngelo DJ. Mini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).

13. Lane AA, Garcia JS, Raulston E, Garzon JL, Galinsky I, Baxter EW, Leonard R, DeAngelo DJ, Lusk MR, Reilly CR, **Stahl M**, Stone RM, Vedula RS, Wadleigh MM, Winer ES, Mughal T, Brooks C, Gupta IV, Stevenson KE, Neuberg DS, Ren S, Konopleva M, Stein A, Pemmaraju N. Tagraxofusp in Combination with Azacitidine and Venetoclax in Newly Diagnosed CD123+ Acute Myeloid Leukemia, Expansion Cohort of a Phase 1b Multicenter Trial. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).
14. Bewersdorf JP, Kewan T, Blaha O, **Stahl M**, Al Ali N, DeZern A, Sekeres MA, Uy G, Carraway H, Desai P, Griffiths EA, Stein EM, Brunner AM, McMahon C, Zeidner JF, Savona MR, Stempel J, Chandhok N, Ramaswamy R, Roboz GJ, Rolles B, Wang E, Harris A, Amaya M, Hawkins H, Grenet J, Shallis RM, Xie Z, Maciejewski J, Sallman DA, Della M Porta, Komrokji R, Zeidan AM. Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) – a Large, Multicenter, Retrospective Analysis. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).
15. Kewan K, Bewersdorf JP, Blaha O, **Stahl M**, Al Ali N, DeZern A, Sekeres M, Uy G, Carraway H, Desai P, Griffiths E, Stein EM, Brunner AM, Amaya M, Zeidner JF, Savona MR, Stempel J, Chandhok N, Roboz GJ, Rolles B, Wang E, Harris A, Shallis RM, Xie Z, Padron E, Maciejewski J, Sallman D, Della Porta M, Komrokji R, Zeidan AM. Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA). ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).
16. Kewan T, Bewersdorf JP, Blaha O, **Stahl M**, Al Ali N, DeZern A, Sekeres M, Carraway H, Desai P, Griffiths E, Stein EM, Brunner AM, Amaya M, Zeidner JF, Savona MR, Stempel J, Chandhok N, Logothetis C, Cochran H, Roboz GJ, Rolles B, Wang E, Harris A, Shallis RM, Xie Z, Padron E, Sallman D, Maciejewski J, Della Porta M, Komrokji R, Zeidan AM. Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) with Missing Molecular Data. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).
17. Kewan T, Bewersdorf JP, Blaha O, **Stahl M**, Al Ali N, DeZern A, Sekeres M, Uy G, Carraway H, Desai P, Griffiths E, Stein EM, Brunner AM, Amaya M, Zeidner JF, Savona MR, Stempel J, Chandhok N, Roboz GJ, Rolles B, Wang E, Harris A, Shallis RM, Xie Z, Padron E, Maciejewski J, Sallman D, Della Porta M, Komrokji R, Zeidan AM. Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogeneic Stem Cell Transplantation (HSCT). ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).
18. Daver N, Stein A, Bixby D, Chai-Ho W, Zeidner JF, Maher K, Stevens D, **Stahl M**, Yee K, Curran E, Ito S, Sochacki A, Sallman D, Hernandez R, Metenou S, Ma B, Kato K, Zeidan AM. Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts). ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).
19. Shimony S, Bewersdorf JP, Shallis RM, Liu Y, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Chen EC, Ramos J, Coleman Lindsley R, Stein AS, DeAngelo DJ, Neuberg DS, Stone RM, Ball BJ, **Stahl M**. What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).
20. Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Coleman Lindsley R, Chen EC, Ramos J, Stein AS, DeAngelo DJ, Neuberg DS, Stone RM, Ball BJ, **Stahl M**. Intensive Induction Chemotherapy vs Hypomethylating Agents + Venetoclax in IDH1- or IDH2-mutant Newly Diagnosed Acute Myeloid Leukemia - A Multicenter Cohort Study. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).

21. Frumm SM, Kim HT, Kelkar AH, Ho VT, Gooptu M, Gibson CJ, Koreth J, Shapiro RM, Romee R, Nikiforow S, Antin JH, Soiffer RJ, Rolles B, Shimony S, Bewersdorf JP, Kewan T, Alhajjah A, Luskin MR, Garcia JS, Chen EC, Lane AA, Wadleigh M, Winer ES, Stone RM, DeAngelo DJ, Zeidan AM, Lindsley C, Cutler C, **Stahl M**. A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).
22. Frumm SM, Kim HT, Kelkar AH, Ho VT, Gooptu M, Gibson CJ, Koreth J, Shapiro RM, Romee R, Nikiforow S, Antin JH, Soiffer RJ, Rolles B, Shimony S, Bewersdorf JP, Kewan T, Alhajjah A, Luskin MR, Garcia JS, Chen EC, Lane AA, Wadleigh M, Winer ES, Stone RM, DeAngelo DJ, Zeidan AM, Lindsley C, Cutler C, **Stahl M**. Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).
23. Rolles B, De Oliveira Filho CM, Keating J, Luskin MR, DeAngelo DJ, Lindsley C, Kim AS, Hem J, Kim CJ, Weeks LD, Wazir M, How J, Marneth AE, Liu Y, Aryee MJ, Tsai HK, **Stahl M**, Mullally A. TP53 mutations and Their Impact on Survival in Patients with Myeloproliferative Neoplasms. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).
24. Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Coleman Lindsley R, Chen EC, Ramos J, Stein AS, DeAngelo DJ, Neuberg DS, Stone RM, Ball BJ, **Stahl M**. Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1-Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).
25. Luskin MR, Murakami MA, Keating J, Winer ES, Garcia JS, **Stahl M**, Wadleigh M, Flamand Y, Neuberg DS, Galinsky I, Leonard R, Hagopian E, Weizer CM, McLanahan C, Stone RM, Wang ES, Stock W, DeAngelo DJ. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Oral Presentation).
26. Shimony S, Garcia JS, Keating J, Chen EC, Luskin MR, **Stahl M**, Neuberg DS, DeAngelo DJ, Stone RM, Coleman Lindsley R. Molecular Ontogeny in AML Is Both Prognostic and Predictive in Patients Treated with Hypomethylating Agents Plus Venetoclax. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Oral Presentation).
27. Bewersdorf JP, Kewan T, Blaha O, **Stahl M**, Al Ali N, DeZern A, Sekeres MA, Uy G, Carraway H, Desai P, Griffiths EA, Stein EM, Brunner AM, McMahon C, Zeidner JF, Savona MR, Stempel J, Chandhok N, Logothetis CN, Roboz GJ, Rolles B, Wang E, Harris A, Amaya M, Hawkins H, Grenet J, Shallis RM, Xie Z, Maciejewski J, Sallman DA, Della Porta M, Komrokji R, Zeidan AM. Validation of the Composite Complete Response (cCR) Definitions in the International Working Group (IWG) 2023 Criteria in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Treated with Hypomethylating Agents (HMA) – a Large, Multicenter, Retrospective Analysis from the Validate Database. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Oral Presentation).
28. Kewan K, Bewersdorf JP, Blaha O, **Stahl M**, Al Ali N, DeZern A, Sekeres M, Uy G, Carraway H, Desai P, Griffiths E, Stein EM, Brunner AM, Amaya M, Zeidner JF, Savona MR, Stempel J, Chandhok N, Roboz GJ, Rolles B, Wang E, Harris A, Shallis R, Padron E, Sallman D, Della Porta M, Komrokji R, Zeidan AM. Clinical Implications of TP53 Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate Database. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Oral Presentation).
29. Jann JC, Hergott CB, Winkler M, Liu Y, Braun B, Charles A, Copson K, Barua S, Meggendorfer M, Nadarajah N, Shimony S, Winer ES, Wadleigh M, Stone RM, DeAngelo DJ, Garcia JS, Haferlach T, Lindsley C, Luskin MR, **Stahl M***, Tothova Z* (*co-senior authors). Subunit-Specific Analysis of Cohesin-Mutant Myeloid Malignancies Reveals Distinct

- Ontogeny and Outcomes. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Oral Presentation).
30. Venkat RK, Redd RA, Aryee MJ, Marneth AE, Kamaz B, Kim CJ, Wazir M, Weeks LD, **Stahl M**, DeAngelo DJ, Lindsley C, Luskin MR, Hobbs GS, How J. No Increased Incidence of Bleeding in Essential Thrombocythemia Patients with Extreme Thrombocytosis. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).
 31. How J, Marneth AE, Kamaz B, Kim CJ, Neuberg DS, Ren S, Wazir M, Weeks LD, **Stahl M**, DeAngelo DJ, Lindsley RC, Luskin MR, Hormoz S, Mullally A. Unlike TET2 and ASXL1, Co-Occurring DNMT3A Mutations are Not Associated with Increased Age in JAK-2 Mutant Myeloproliferative Neoplasms (MPNs). ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).
 32. How J, Leiva O, Marneth AE, Kamaz B, Kim CJ, Weeks LD, Wazir M, **Stahl M**, DeAngelo DJ, Lindsley RC, Luskin MR, Hobbs GS. Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes. ASH 2023 Annual Meeting, San Diego, CA, 2023 (Poster Presentation).
 33. Khawaja MR, Rafeh Naqash A, Schneider R, Shastri A, **Stahl M**, Moser JC, Karim NA, Madanat Y, Jonas B, Stein E, Gadgeel S, McCloskey J, Gollerkeri A, Perea R, Chutake Y, Agarwal S, Henrick P, Daver N. Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of KT-253, a Targeted Protein Degradator of MDM2, in Patients with Relapsed/Refractory (R/R) Solid Tumors, Lymphoma, High Grade Myeloid Malignancies and Acute Lymphoblastic Leukemia (ALL). 2024 ASCO Annual Meeting; Chicago, IL, 2024 (Poster Presentation).
 34. Stone RM, DeAngelo DJ, Letai AC, Galinsky I, Weiner H, Halpin A, Noyes L, Smith A, Lombardi C, Leonard R, Fell G, Flammand Y, Konopleva M, Wadleigh M, **Stahl M**, Chen E, Volpe V, Winer ES, Garcia JS, Luskin MR, Patel AA. Final Analysis of the Phase I study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia. 2024 ASH Annual Meeting; San Diego, CA, 2024 (Poster Presentation).
 35. Potnis K, Ito S, Patel KK, Shallis RM, Podoltsev NA, Kewan T, Stempel JM, Mendez L, Huntington SF, **Stahl M**, Zeidan AM, Bewersdorf JP, Goshua G. Cost-effectiveness of eltrombopag plus immunosuppressive therapy versus immunosuppressive therapy alone in adults with severe aplastic anemia in the United States. 2024 ASH Annual Meeting; San Diego, CA, 2024 (Poster Presentation).
 36. Chin KK, Derkach A, Famulare C, Gupta GK, Borge PD, Geyer MB, Goldberg AD, Haque T, Park JH, Roeker LE, Tallman MS, **Stahl M**, Stein EM. Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment Modifications and Associated Outcomes in IDH-mutant AML. 2024 ASH Annual Meeting; San Diego, CA (Poster Presentation).
 37. Jang JE, Stanojevic M, Piccinelli S, Sheffer M, Birch G, Shapiro R, **Stahl M**, Koreth J, Wu CJ, Soiffer RJ, Ritz J, Tarannum M, Romee R. IL12-Engineered CAR Memory-like NK Cells Targeting Mesothelin-Expressing Acute Myeloid Leukemia Demonstrate Promising Efficacy. 2024 ASH Annual Meeting; San Diego, CA, 2024 (Poster Presentation).
 38. Garcia-Manero G, Abaza Y, Greenberg P, Haque T, Kennedy KV, DellaPorta M, Ooi M, **Stahl M**, Xie Z, Mangaonkar A, Desai P, DeZern A, Garnier A, Meunier M, Pelizzari AM, Platzbecker U, Sockel K, Kishtagari A, Lu H, Manganelli L, Ji L, Yan Z, Li Y, Roy M, Gatlik E, Singh A, Beaulieu V, Pelletier M, Rauch P, Singh GH. Myelodysplastic Syndromes – Clinical and Epidemiological. 2024 ASH Annual Meeting; San Diego, CA, 2024 (Poster Presentation).
 39. Piccinelli S, Bourgeois W, Dong H, Ali A, Shapiro R, **Stahl M**, Soiffer RJ, Wu CJ, Ritz J, Chen J, Armstrong S, Koreth J, Romee R. A novel TCR-mimetic CAR overcomes resistance and demonstrates synergism with menin inhibition in NPM1-mutant AML. 2024 ASH Annual Meeting; San Diego, CA, 2024 (Poster Presentation).
 40. Komrokji R, Schwabkey Z, Ali NA, Aguirre L, **Stahl M**, Ball S, Mason E, Savona M, Santini V, Consagra A, Platzbecker U, Kubasch AS, Madanat Y, Fenaux P, Zhao LP, Sekeres M,

- Chandhok N, Porta MD, Lanino L, Dezern A, Sallman D, Padron E, Xie Z, Sasaki K, Takaoka K, Jain A, Del Rey Gonzalez M, Campelo MD, Garcia-Manero G. Myelodysplastic Syndromes with Concomitant *SF3B1* Mutation and Deletion of the Long Arm of Chromosome 5: Outcomes and Response to Treatment. 2024 ASH Annual Meeting; San Diego, CA, 2024 (Poster Presentation).
41. Shimony S, Wang Y, Cronin A, Walsh T, Charles A, Slopen N, **Stahl M**, Bystrom R, Luskin MR, Abel GA, DeAngelo DJ, Stone RM, Lindsley RC, Hantel A. Impact of social determinants of health on overall survival in patients with AML by European LeukemiaNet risk group. 2024 ASH Annual Meeting; San Diego, CA, 2024 (Poster Presentation).
 42. Bewersdorf JP, Hasle V, Shallis RM, Thompson E, Lopes de Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, **Stahl M**, Kewan T, Halene S, Haferlach T, Fox B, Zeidan AM. Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab. 2024 ASH Annual Meeting; San Diego, CA, 2024 (Poster Presentation).
 43. Chen EC, Liu Y, Bell HL, Galinsky I, Luskin MR, Winer ES, **Stahl M**, Vedula R, Volpe V, DeAngelo DJ, Ryan, Minihane EJ, Hersch M, Leonard R, Neuberg D, Stone RM, Letai A, Lane AA, Garcia JS. Dual BCLxL and BCL2 inhibition with navitoclax (NAV), venetoclax (VEN), and decitabine (DEC) for advanced myeloid neoplasms (MN): safety and biological activity in a phase 1 study. 2024 ASH Annual Meeting; San Diego, CA (Poster Presentation).
 44. Rolles B, Chatain N, Görg R, Vieri M, Tillman N, Bourgeois MG, Christen D, Walter J, Hillerbrandt AC, Romine KA, Taylor K, Bertram J, Jost E, Koschmieder S, Beier F, **Stahl M**, Brümmendorf TH, Rink L, Wessels I. ZIP10 (*SLC39A10*) is an important transport protein in acute myeloid leukemia. 2024 ASH Annual Meeting; San Diego, CA, 2024 (Poster Presentation).
 45. Iat A, Bewersdorf JP, Gilhodes J, Liu Y, Shallis R, Boussi L, Žučenka A, Bystrom RP, DeAngelo D, Berton G, Soua A, Ling K, Aguirre LE, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Stein E, Goldberg AD, Zeidan AM, Cluzeau T, Shimony S, **Stahl M**, Garcia S. Venetoclax-based Therapy Versus Intensive Chemotherapy Followed by Allogeneic Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia. 2024 ASH Annual Meeting; San Diego, CA, 2024 (Poster Presentation).
 46. Getz TM, Kewan T, Bewersdorf JP, Stempel JM, Lanino L, Wei W, Al Ali NH, DeZern AE, Sekeres MA, Uy GL, Carraway HE, Desai P, Griffiths EA, Stein EM, Brunner AM, McMahon C, Shallis RM, Zeidner JF, Savona MR, Ball S, Chandhok NS, Logothetis C, Bidikian A, Roboz GJ, Rolles B, Wang ES, Harris AC, Amaya ML, Hawkins H, Grenet J, Xie Z Madanat YF, Abaza Y, Badar T, Haferlach T, Maciejewski J, Sallman DA, Enjeti AK, Al-Rabi K, Halahleh K, Hiwase D, Diez-Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al-Kali A, Ogawa S, Nannya Y, **Stahl M**, Della Porta MG, Komrokji RS, Zeidan AM. Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database. 2024 ASH Annual Meeting; San Diego, CA, 2024 (Poster Presentation).
 47. Boussi L, Bewersdorf JP, Liu Y, Shallis R, Aguirre L, Žučenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer ES, Chen E, Wadleigh M, Zeidan AM, Goldberg A, Stein E, Shimony S, **Stahl M**. Outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients with chromosome 5 and 7 abnormalities. 2024 ASH Annual Meeting; San Diego, CA, 2024 (Poster Presentation).
 48. Zhang J, Shimony S, Liu Y, Ling K, Inyang EA, Chen E, Aguirre L, Bystrom R, Rolles B, Stone R, DeAngelo D, **Stahl M**, Tiao E. Impact of molecular ontogeny on hematological recovery in AML patients treated with hypomethylating agent plus venetoclax therapy. 2024 ASH Annual Meeting; San Diego, CA, 2024 (Poster Presentation).
 49. Bystrom RP, Bewersdorf JP, Liu Y, Schaefer E, Shallis RM, Boussi L, Zucenka A, Garciaz S, Aguirre LE, DeAngelo DJ, Stone RM, Luskin MR, Garcia JS, Winer ES, Chen EC, Wadleigh M, Ling K, Stein EM, Goldberg AD, Zeidan AM, Shimony S, **Stahl M**. The Prognostic and

Maximilian Stahl, MD

Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia – an International Multicenter Cohort Study. 2024 ASH Annual Meeting; San Diego, CA, 2024 (Poster Presentation).

50. Aguirre LE, Kim HT, Emariah H, Frumm SM, Kelkar AH, Ho VT, Gooptu M, Koreth J, Shapiro R, Romee R, Nikiforow S, Antin JH, Soiffer RJ, Rolles B, Shimony S, Luskin MR, Garcia JS, Ling K, Chen EC, Wadleigh M, Winer ES, Stone RM, DeAngelo DJ, Ali MHA, Cutler CS, Komrokji RS, **Stahl M**. Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes. 2024 ASH Annual Meeting; San Diego, CA, 2024 (Poster Presentation).
51. Rolles B, Bewersdorf JP, Kewan T, Blaha O, Stempel JM, Lanino L, Al Ali NH, DeZern AE, Sekeres MA, Uy GL, Carraway HE, Desai P, Griffiths EA, Stein EM, Brunner AM, McMahon CM, Shallis RM, Zeidner JF, Savona MR, Frumm SM, Barua S, Chandhok NS, Logothetis C, Bidikian A, Getz TM, Roboz GJ, Wang ES, Harris AC, Amaya ML, Hawkins H, Ball S, Grenet J, Xie Z, Madanat YF, Abaza Y, Badar T, Haferlach T, Maciejewski J, Sallman D, Enjeti AK, Al-Rabi K, Halahleh K, Hiwase D, Diez-Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al-Kali A, Ogawa S, Nannya Y, Della Porta MG, Komrokji RS, Zeidan AM, **Stahl M**. Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database. ASH 2024 Annual Meeting, San Diego, CA, December 2024 (Oral presentation).
52. Alhajjah A, Patel KK, Shallis RM, Podoltsev NA, Kewan T, Stempel JM, Mendez L, Huntington SF, **Stahl M**, Zeidan AM, Goshua G, Bewersdorf JP. Cost-Effective Analysis for Allogeneic Hematopoietic Stem Cell Transplant (HSCT) versus Consolidation Chemotherapy for Intermediate Risk Acute Myeloid Leukemia Patients. ASH 2024 Annual Meeting, San Diego, CA, December 2024 (Oral presentation).

Regional

None

Professional Service

Peer Review Groups/Grant Study Sections:

None

Journals:

Editorial Boards

2020-present Editorial board, *Leukemia & Lymphoma*

Reviewer

Acta Haematologica, American Journal of Hematology, Annals of Hematology and Oncology, Blood, Blood Advances, British Journal of Haematology, Cancer, Clinical Cancer Research, Haematologica, Journal of Hematology and Blood Disorders, Leukemia, Leukemia & Lymphoma

Professional Organizations:

American Society of Hematology (2024)

2017-present Member
2023 Member, ASH 2023 Abstract Selection Review Committee for Abstracts in Myelodysplastic Syndromes
2024 Member, ASH 2024 Abstract Selection Review Committee for Abstracts in Acute Myeloid Leukemia

American Society of Clinical Oncology (ASCO)

2017-present	Member
2024	Co-Chair, ASCO 2024 Educational Session on TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes

Yale University/Hospital System:

University Committees

None

Medical School Committees

None

Departmental Committees

2016-2017	Coordinator Investigation Distinction Pathway Yale Internal Medicine Residency Program
2017-2018	Member, Internal Medicine Residency Selection Committee, Department of Internal Medicine
2017-2018	Member, Residency Program Training Committee, Department of Internal Medicine
2017-2018	Member, Executive Council, Internal Medicine Residency Program, Department of Internal Medicine

Hospital Committees

None

Public Service / Media Presence:

Public Service:

2023	Invited speaker, at the AAMDSIF Patient and Family Conference, Aplastic Anemia and MDS International Foundation (AAMDSIF), New Haven, CT
------	--

Media Presence:

2015-2018	Founder and Co-Chair of “Yale 20” – a peer-teaching YouTube channel by Yale Internal Medicine Residency Program
-----------	---

Bibliography:

Peer-Reviewed Original Research

1. **Stahl M**, Stahl K, Brubacher MB, Forrest JN Jr. Divergent CFTR orthologs respond differently to the channel inhibitors CFTRinh-172, glibenclamide, and GlyH-101. *Am J Physiol Cell Physiol*. 2012 Jan 1;302(1):C67-C76. PMID: 21940661, PMCID: PMC3328903
2. Stahl K*, **Stahl M***, de Jonge HR, Forrest JN Jr. ANP and CNP activate CFTR expressed in *Xenopus laevis* oocytes by direct activation of PKA. *J Recept Signal Transduct Res*. 2015;35(5):493-504. PMID: 26016495
3. Zeidan AM, **Stahl M**, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. *Blood*. 2018 Feb 15;131(7):818-821. PMID: 29259002, PMCID: PMC6410557
4. **Stahl M**, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. *Blood Adv*. 2018 Apr 24;2(8):923-932. PMID: 29685952, PMCID: PMC5916007
5. Zeidan AM, **Stahl M**, DeVeaux M, Giri S, Huntington S, Podoltsev N, Wang R, Ma X, Davidoff AJ, Gore SD. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?. *Blood Cancer J*. 2018 Jun 11;8(6):55. PMID: 29891916, PMCID: PMC5995881
6. **Stahl M**, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. *Blood Adv*. 2018 Jul 24;2(14):1765-1772. PMID: 30037803, PMCID: PMC6058241
7. **Stahl M**, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. *Biol Blood Marrow Transplant*. 2018 Aug;24(8):1754-1758. PMID: 29649620
8. **Stahl M**, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM. Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey. *Leuk Lymphoma*. 2018 Nov;59(11):2723-2726. PMID: 29667455
9. **Stahl M**, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM. Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. *Leuk Lymphoma*. 2019 Jan;60(1):246-249. PMID: 29963936
10. Kim TK, DeVeaux M, **Stahl M**, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation. *Ann Hematol*. 2019 Jan;98(1):237-240. PMID: 30027436
11. Zeidan AM, Zhu W, **Stahl M**, Wang R, Huntington SF, Giri S, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. RBC transfusion independence among lower risk MDS patients receiving

- hypomethylating agents: a population-level analysis. *Leuk Lymphoma*. 2019 Dec;60(13):3181-3187. PMID: 31170846
12. **Stahl M**, Bewersdorf JP, Giri S, Wang R, Zeidan AM. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. *Haematologica*. 2020 Jan;105(1):102-111. PMID: 31004015, PMCID: PMC6939518
13. Zeidan AM, Hu X, Zhu W, **Stahl M**, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. *Leuk Lymphoma*. 2020 Feb;61(2):397-408. PMID: 31570040, PMCID: PMC7732188
14. Shallis RM*, **Stahl M***, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, König H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukhereje S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. *Leuk Lymphoma*. 2020 May;61(5):1220-1225. PMID: 32100599, PMCID: PMC8273667 (*co-first author)
15. Pine AB, Chokr N, **Stahl M**, Steensma DP, Sekeres MA, Litzow MR, Luger SM, Stone RM, Greenberg PL, Bejar R, Bewersdorf JP, Gore SD, Zeidan AM. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. *Leuk Lymphoma*. 2020 Jun;61(6):1455-1464. PMID: 32026740
16. Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Rampal RK, Tallman MS, Zeidan AM, **Stahl M**. Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. *Clin Lymphoma Myeloma Leuk*. 2020 Oct;20(10):e712-e723. PMID: 32669244, PMCID: PMC7541411
17. Bewersdorf JP, Giri S, Tallman MS, Zeidan AM, **Stahl M**. Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia-A systematic review and meta-analysis. *Transfusion*. 2020 Oct;60(10):2360-2369. PMID: 32776542, PMCID: PMC8631180
18. Bewersdorf JP, Giri S, Wang R, Williams RT, Tallman MS, Zeidan AM, **Stahl M**. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. *Haematologica*. 2020 Nov 1;105(11):2659-2663. PMID: 33131256, PMCID: PMC7604631
19. **Stahl M**, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, König H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukherjee S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. *Leukemia*. 2020 Dec;34(12):3149-3160. PMID: 32132655, PMCID: PMC8155811
20. Cortes J, Podoltsev N, Kantarjian H, Borthakur G, Zeidan AM, **Stahl M**, Taube T, Fagan N, Rajeswari S, Uy GL. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. *Int J Hematol*. 2021 Jan;113(1):92-99. PMID: 32951163
21. Xiao W, Chan A, Waarts MR, Mishra T, Liu Y, Cai SF, Yao J, Gao Q, Bowman RL, Koche RP, Csete IS, DelGaudio NL, Derkach A, Baik J, Yanis S, Famulare CA, Patel M, Arcila ME, **Stahl M**, Rampal RK, Tallman MS, Zhang Y, Dogan A, Goldberg AD, Roshal M, Levine RL. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. *Blood*. 2021 Mar 11;137(10):1377-1391. PMID: 32871587, PMCID: PMC7955409
22. **Stahl M**, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King AC, Daniyan AF, Famulare C, Cuello BM, Horvat TZ, Abdel-Wahab O, Levine RL, Viny AD, Stein EM, Cai SF, Roshal M, Tallman MS, Goldberg AD. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. *Blood Adv*. 2021 Mar 9;5(5):1552-1564. PMID: 33687434, PMCID: PMC7948282
23. Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Tallman MS, Rampal RK, Zeidan AM, **Stahl M**. Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic

- review and meta-analysis. *Leukemia*. 2021 Jun;35(6):1643-1660. PMID: 32868875, PMCID: PMC7917159
24. **Stahl M**, Narendra V, Jee J, Derkach A, Maloy M, Geyer MB, Mato AR, Roeker LE, Tallman MS, Shah GL, Daniyan A, Goldberg AD. Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. *Leuk Lymphoma*. 2021 Aug;62(8):1940-1948. PMID: 34180767, PMCID: PMC10080398
25. Bewersdorf JP, Sheth AH, Vetsa S, Grimshaw A, Giri S, Podoltsev NA, Gowda L, Tamari R, Tallman MS, Rampal RK, Zeidan AM, **Stahl M**. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis. *Transplant Cell Ther*. 2021 Oct;27(10):873.e1-873.e873.e13. PMID: 34052505, PMCID: PMC8478722
26. Bewersdorf JP, Derkach A, Gowda L, Menghrajani K, DeWolf S, Ruiz JD, Ponce DM, Shaffer BC, Tamari R, Young JW, Jakubowski AA, Gyurkocza B, Chan A, Xiao W, Glass J, King AC, Cai SF, Daniyan A, Famulare C, Cuello BM, Podoltsev NA, Roshal M, Giralt S, Perales MA, Seropian S, Cho C, Zeidan AM, Prebet T, Stein EM, Tallman MS, Goldberg AD, **Stahl M**. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. *Leuk Lymphoma*. 2021 Dec;62(14):3394-3401. PMID: 34477024, PMCID: PMC9012492
27. Bewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, Gowda L, Cho C, Tallman MS, Zeidan AM, **Stahl M**. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis. *Transplant Cell Ther*. 2021 Dec;27(12):997.e1-997.e997.e11. PMID: 34551341, PMCID: PMC9533376
28. King AC, Weis TM, Derkach A, Ball S, Pandey M, Mauro MJ, Goldberg AD, **Stahl M**, Famulare C, Tallman MS, Wang ES, Kuykendall AT, Rampal RK. Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. *Am J Hematol*. 2022 Jan 1;97(1):E7-EE10. PMID: 34674293
29. North K, Benbarche S, Liu B, Pangallo J, Chen S, **Stahl M**, Bewersdorf JP, Stanley RF, Erickson C, Cho H, Pineda JMB, Thomas JD, Polaski JT, Belleville AE, Gabel AM, Udy DB, Humbert O, Kiem HP, Abdel-Wahab O, Bradley RK. Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells. *Nat Biotechnol*. 2022 Jul;40(7):1103-1113. PMID: 35241838, PMCID: PMC9288984
30. Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, Bewersdorf JP, Saliba AN, Correia GSC, Murthy G, Duvall A, Burkart M, **Stahl M**, Liu Y, Dinner S, Palmisiano N, Litzow MR, Foran JM. Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. *Am J Hematol*. 2022 Jul;97(7):E232-E235. PMID: 35338673
31. Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, **Stahl M**. Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax. *Leuk Res*. 2022 Nov;122:106942. PMID: 36108424
32. Shimony S, Rozental A, Bewersdorf JP, Goldberg AD, Stein EM, Grimshaw AA, Stone RM, DeAngelo DJ, Wolach O, **Stahl M**. Investigational venetoclax combination therapy in acute myeloid leukemia - a systematic review and meta-analysis. *Haematologica*. 2022 Dec 1;107(12):2955-2960. PMID: 36453519, PMCID: PMC9713559
33. **Stahl M**, Derkach A, Farnoud N, Bewersdorf JP, Robinson T, Famulare C, Cho C, Devlin S, Menghrajani K, Patel MA, Cai SF, Miles LA, Bowman RL, Geyer MB, Dunbar A, Epstein-Peterson ZD, McGovern E, Schulman J, Glass JL, Taylor J, Viny AD, Stein EM, Getta B, Arcila ME, Gao Q, Barker J, Shaffer BC, Papadopoulos EB, Gyurkocza B, Perales MA, Abdel-Wahab O, Levine RL, Giralt SA, Zhang Y, Xiao W, Pai N, Papaemmanuil E, Tallman MS, Roshal M, Goldberg AD. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. *Am J Hematol*. 2023 Jan;98(1):79-89. PMID: 36251406, PMCID: PMC10080561
34. Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ*, **Stahl M***. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors. *Leuk Lymphoma*. 2023 Jan;64(1):188-196. PMID: 36287540, PMCID: PMC9905301

35. Wang E, Pineda JMB, Kim WJ, Chen S, Bourcier J, **Stahl M**, Hogg SJ, Bewersdorf JP, Han C, Singer ME, Cui D, Erickson CE, Tittley SM, Penson AV, Knorr K, Stanley RF, Rahman J, Krishnamoorthy G, Fagin JA, Creger E, McMillan E, Mak CC, Jarvis M, Bossard C, Beaupre DM, Bradley RK, Abdel-Wahab O. Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia. *Cancer Cell*. 2023 Jan 9;41(1):164-180.e8. PMID: 36563682, PMCID: PMC9839614
36. Bewersdorf JP, Patel KK, Goshua G, Shallis RM, Podoltsev NA, **Stahl M**, Stein EM, Huntington SF, Zeidan AM. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia. *Leuk Lymphoma*. 2023 Feb;64(2):454-461. PMID: 36493798, PMCID: PMC9957935
37. Przespolewski A, Goldberg AD, Talati C, Fazal S, Vachhani P, Sanikommu SR, Thota S, Waksal J, Ball B, Famulare C, **Stahl M**, Baron J, Griffiths EA, Thompson JE, Sweet K, Wang ES. Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia. *Blood*. 2023 Mar 23;141(12):1489-1493. PMID: 36493344
38. Badar T, Litzow MR, Shallis RM, Patel A, Saliba AN, Burkart M, Bewersdorf JP, **Stahl M**, De Camargo Correia GS, Guru Murthy GS, Abaza Y, Duvall A, Bradshaw D, Kota V, Dinner S, Goldberg AD, Palmisiano N, Al Kali A, Atallah E. Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. *Cancer*. 2023 Mar 15;129(6):934-945. PMID: 36545710
39. Badar T, Atallah E, Shallis R, Saliba AN, Patel A, Bewersdorf JP, Grenet J, **Stahl M**, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kubiak M, Dinner S, Goldberg AD, Abaza Y, Murthy GSG, Kota V, Litzow MR. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). *Leukemia*. 2023 Apr;37(4):799-806. PMID: 36807649
40. Shimony S, Fell GG, Chen EC, Tsai HK, Wadleigh M, Winer ES, Garcia JS, Luskin MR, **Stahl M**, Neuberg DS, DeAngelo DJ, Lindsley RC, Stone RM. FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients age 60 years. *Blood Adv*. 2023 May 10;bloodadvances.2023009748. PMID: 37163357
41. Sherban A, Fredman D, Shimony S, Yeshurun M, Raanani P, **Stahl M**, Gafter-Gvili A, Wolach O. Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review. *Leuk Res*. 2023 Aug 4;133:107368. PMID:37598660
42. **Stahl M**, Giblin G, Liu Y, Winer ES, Garcia JS, Chen E, Wadleigh M, Ling K, Lindsley RC, Shimony S, Copson K, Charles A, DeAngelo DJ, Stone RM, Nohria A, Luskin MR. Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia. *Leuk Res*. 2023 Sep;132:107351. PMID: 37451200
43. Bewersdorf JP*, **Stahl M***, Taylor J, Mi X, Chandhok NS, Watts J, Derkach A, Wysocki M, Lu SX, Bourcier J, Hogg SJ, Rahman J, Chaudhry S, Totiger TM, Abdel-Wahab O, Stein EM. E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. *Leukemia*. 2023 Oct 9. PMID: 37814121; PMCID: PMC10681888 (* co-first author).
44. Lane AA, Garcia JS, Raulston EG, Garzon JL, Galinsky I, Baxter EW, Leonard R, DeAngelo DJ, Luskin MR, Reilly CR, **Stahl M**, Stone RM, Vedula RS, Wadleigh MM, Winer ES, Mughal T, Brooks C, Gupta IV, Stevenson KE, Neuberg DS, Ren S, Keating J, Konopleva M, Stein A, Pemmaraju N. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. *Blood Adv*. 2024 Feb 13;8(3):591-602. PMID: 38052038.
45. Shimony S, Bewersdorf JP, Shallis RM, Liu Y, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Lindsley RC, Chen EC, Ramos Perez J, Stein A, DeAngelo DJ, Neuberg DS, Stone RM, Ball B, **Stahl M**. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. *Leukemia*. 2024 Apr;38(4):762-768. doi: 10.1038/s41375-024-02175-0. PMID: 38378841.
46. Izzo F, Myers RM, Ganesan S, Mekerishvili L, Kottapalli S, Prieto T, Eton EO, Botella T, Dunbar AJ, Bowman RL, Sotelo J, Potenski C, Mimitou EP, **Stahl M**, El Ghaity-Beckley S, Arandela J, Raviram R, Choi DC, Hoffman R, Chaligné R, Abdel-Wahab O, Smibert P, Ghobrial IM, Scandura JM, Marcellino

- B, Levine RL, Landau DA. Mapping genotypes to chromatin accessibility profiles in single cells. *Nature*. 2024 May;629(8014):1149-1157. doi: 10.1038/s41586-024-07388-y. PMID: 38720070; PMCID: PMC11139586.
47. Badar T, Nanaa A, Atallah E, Shallis RM, Craver EC, Li Z, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, Duvall A, Burkart M, Bradshaw D, Abaza Y, **Stahl M**, Palmisiano N, Murthy GSG, Zeidan AM, Kota V, Patnaik MM, Litzow MR. Prognostic impact of 'multi-hit' *versus* 'single hit' *TP53* alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases. *Haematologica*. 2024 May 30. doi: 10.3324/haematol.2024.285000. PMID: 38813716.
48. Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Bystrom R, Lindsley RC, Chen EC, Ramos Perez JM, Stein AS, Pullarkat VA, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garcia S, Ball BJ, **Stahl M**. Intensive Induction Chemotherapy versus Hypomethylating Agents in Combination with Venetoclax in NPM1-mutant AML. *Blood Adv*. 2024 Jun 28;bloodadvances.2024012858. doi: 10.1182/bloodadvances.2024012858. Epub ahead of print. PMID: 38941537.
49. Shimony S, Garcia JS, Keating J, Chen EC, Lusk MR, **Stahl M**, Neuberg DS, DeAngelo DJ, Stone RM, Lindsley RC. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. *Leukemia*. 2024 Jul;38(7):1494-1500. doi: 10.1038/s41375-024-02230-w. PMID: 38538860; PMCID: PMC11216982.
50. Jann JC, Hergott CB, Winkler M, Liu Y, Braun B, Charles A, Copson KM, Barua S, Meggendorfer M, Nadarajah N, Shimony S, Winer ES, Wadleigh M, Stone RM, DeAngelo DJ, Garcia JS, Haferlach T, Lindsley RC, Lusk MR, **Stahl M***, Tothova Z*. Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes. *Leukemia*. 2024 Jul 20. doi: 10.1038/s41375-024-02347-y. PMID: 39033241 (* co-senior author).
51. Bewersdorf JP, Patel KK, Shallis RM, Podoltsev NA, Kewan T, Stempel J, Mendez L, **Stahl M**, Stein EM, Huntington SF, Goshua G, Zeidan AM. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with *FLT3*-mutant acute myeloid leukemia. *Leuk Lymphoma*. 2024 Aug;65(8):1136-1144. doi: 10.1080/10428194.2024.2344052. PMID: 38648559; PMCID: PMC11265977.
52. Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg A, Stein E, Marcucci G, Bystrom RP, Lindsley RC, Chen EC, Ramos J, Stein A, Pullarkat V, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garcia S, Ball B, **Stahl M**. Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study. *Am J Hematol*. 2024 Aug;99(8):1640-1643. doi: 10.1002/ajh.27366. PMID: 38751104.
53. Ghosh S, Nguyen MT, Choi HE, **Stahl M**, Kühn AL, Van der Auwera S, Grabe HJ, Völzke H, Homuth G, Myers SA, Hogaboam CM, Noth I, Martinez FJ, Petsko GA, Glimcher LH. R1OK2 transcriptionally regulates TRiC and dyskerin complexes to prevent telomere shortening. *Nat Commun*. 2024 Aug 20;15(1):7138. doi: 10.1038/s41467-024-51336-3. PMID: 39164231; PMCID: PMC11335878.

In Press: Peer-Reviewed Original Research In Press

None

Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

1. **Stahl M**, Gore SD, Vey N, Prebet T. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. *Expert Opin Investig Drugs*. 2016;25(3):307-317. PMID: 26807602.
2. **Stahl M**, Gedrich R, Peck R, LaVallee T, Eder JP. Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors. *Immunotherapy*. 2016 Jun;8(7):767-774. PMID: 27349976.
3. Zeidan AM, **Stahl M**, Komrokji R. Emerging biological therapies for the treatment of myelodysplastic syndromes. *Expert Opin Emerg Drugs*. 2016 Sep;21(3):283-300. PMID: 27486848.

4. **Stahl M**, Kohrman N, Gore SD, Kim TK, Zeidan AM, Prebet T. Epigenetics in Cancer: A Hematological Perspective. *PLoS Genet*. 2016 Oct;12(10):e1006193. PMID: 27723796, PMCID: PMC5065123.
5. **Stahl M**, Kim TK, Zeidan AM. Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. *World J Stem Cells*. 2016 Oct 26;8(10):316-331. PMID: 27822339, PMCID: PMC5080639.
6. Podoltsev NA, **Stahl M**, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. *Blood Rev*. 2017 Mar;31(2):43-62. PMID: 27745715.
7. **Stahl M**, Zeidan AM. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. *Expert Rev Hematol*. 2017 Apr;10(4):345-364. PMID: 28277851.
8. **Stahl M**, Zeidan AM. Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?. *Cancer*. 2017 May 15;123(6):911-914. PMID: 28094843.
9. **Stahl M**, Zeidan AM. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. *Cancer*. 2017 May 15;123(10):1703-1713. PMID: 28192601.
10. **Stahl M**, Zeidan AM. Management of myelofibrosis: JAK inhibition and beyond. *Expert Rev Hematol*. 2017 May;10(5):459-477. PMID: 28395559.
11. Gbolahan OB, Zeidan AM, **Stahl M**, Abu Zaid M, Farag S, Paczesny S, Konig H. Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment. *Int J Mol Sci*. 2017 Jul 31;18(8):1660. PMID: 28758974, PMCID: PMC5578050.
12. **Stahl M**, Lu BY, Kim TK, Zeidan AM. Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?. *Target Oncol*. 2017 Aug;12(4):413-447. PMID: 28664386.
13. Zeidan AM, **Stahl M**, Sekeres MA, Steensma DP, Komrokji RS, Gore SD. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. *Cancer*. 2017 Oct 1;123(19):3662-3672. PMID: 28759108.
14. Li AW, Yin ES, **Stahl M**, Kim TK, Panse G, Zeidan AM, Leventhal JS. The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies. *Blood Rev*. 2017 Nov;31(6):370-388. PMID: 28732587.
15. Uy N, Nadeau M, **Stahl M**, Zeidan AM. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia. *J Blood Med*. 2018;9:67-74. PMID: 29713210, PMCID: PMC5908210.
16. Shallis RM, Chokr N, **Stahl M**, Pine AB, Zeidan AM. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. *Expert Rev Hematol*. 2018 Sep;11(9):715-726. PMID: 30024293.
17. Bewersdorf JP, Shallis R, **Stahl M**, Zeidan AM. Epigenetic therapy combinations in acute myeloid leukemia: what are the options?. *Ther Adv Hematol*. 2019;10:2040620718816698. PMID: 30719265, PMCID: PMC6348528.
18. Liu Y, Bewersdorf JP, **Stahl M**, Zeidan AM. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?. *Blood Rev*. 2019 Mar;34:67-83. PMID: 30553527.
19. **Stahl M**, Goldberg AD. Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets. *Curr Oncol Rep*. 2019 Mar 23;21(4):37. PMID: 30904967.
20. Chokr N, Pine AB, Bewersdorf JP, Shallis RM, **Stahl M**, Zeidan AM. Getting personal with myelodysplastic syndromes: is now the right time?. *Expert Rev Hematol*. 2019 Apr;12(4):215-224. PMID: 30977414, PMCID: PMC6540985.
21. Bewersdorf JP, **Stahl M**, Zeidan AM. Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. *Expert Rev Anticancer Ther*. 2019 May;19(5):393-404. PMID: 30887841, PMCID: PMC6527485.
22. Bewersdorf JP, **Stahl M**, Zeidan AM. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?. *Leuk Lymphoma*. 2019 Jun;60(6):1354-1369. PMID: 30652518.
23. Bewersdorf JP, **Stahl M**, Zeidan AM. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of

- relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant. *Expert Rev Hematol*. 2019 Aug;12(8):575-578. PMID: 31225770.
24. **Stahl M**, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. *Br J Haematol*. 2019 Oct;187(2):157-162. PMID: 31410848.
25. **Stahl M**, Tallman MS. Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all. *Leuk Lymphoma*. 2019 Dec;60(13):3107-3115. PMID: 31842650, PMCID: PMC7479633.
26. Agrawal V, Gbolahan OB, **Stahl M**, Zeidan AM, Zaid MA, Farag SS, Konig H. Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia. *Curr Cancer Drug Targets*. 2020;20(7):473-489. PMID: 32357813.
27. Shallis RM, **Stahl M**, Bewersdorf JP, Hendrickson JE, Zeidan AM. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. *Expert Rev Hematol*. 2020 May;13(5):489-499. PMID: 32248712.
28. Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, **Stahl M**, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, Konig H, Komrokji R, Deininger M, Cirici BX, Bhatt VR, Silverman LR, Erba HP, Fenaux P, Platzbecker U, Santini V, Wang ES, Tallman MS, Stone RM, Mascarenhas J. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. *Lancet Haematol*. 2020 Aug;7(8):e601-e612. PMID: 32563283, PMCID: PMC7302757.
29. **Stahl M**, Epstein-Peterson ZD, Intlekofer AM. Oncogenic Mechanisms and Therapeutic Targeting of Metabolism in Leukemia and Lymphoma. *Cold Spring Harb Perspect Med*. 2021 Jul 1;11(7):a035477. PMID: 32816875, PMCID: PMC8247556.
30. Bewersdorf JP, Tallman MS, **Stahl M**. Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept. *Curr Opin Oncol*. 2021 Nov 1;33(6):658-669. PMID: 34341323.
31. Shimony S, Stone RM, **Stahl M**. Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes. *Curr Opin Hematol*. 2022 Mar 1;29(2):63-73. PMID: 34966123.
32. Shallis RM, Bewersdorf JP, **Stahl M**, Halene S, Zeidan AM. Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?. *Cancers (Basel)*. 2022 May 14;14(10):2434. PMID: 35626039, PMCID: PMC9140008.
33. Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultonwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, **Stahl M**, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. *Leukemia*. 2022 Dec;36(12):2939-2946. PMID: 36266326.
34. Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Della Porta MG, **Stahl M**, Steensma D, Xu ML, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. *Leukemia*. 2022 Dec;36(12):2934-2938. PMID: 36335264.
35. Shimony S, **Stahl M**, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. *Am J Hematol*. 2023 Mar;98(3):502-526. PMID: 36594187.
36. Zeidan AM, Platzbecker U, Bewersdorf JP, **Stahl M**, Adès L, Borate U, Bowen D, Buckstein R, Brunner A, Carraway HE, Daver N, Díez-Campelo M, de Witte T, DeZern AE, Efficace F, Garcia-Manero G, Garcia JS, Germing U, Giagounidis A, Griffiths EA, Hasserjian RP, Hellström-Lindberg E, Iastrebner M, Komrokji R, Kulasekararaj AG, Malcovati L, Miyazaki Y, Odenike O, Santini V, Sanz G, Scheinberg P, Stauder R, Van de Loosdrecht AA, Wei AH, Sekeres MA, Fenaux P. Consensus proposal

- for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. *Blood*. 2023 Apr 27;141(17):2047-2061. PMID: 36724453.
37. Xie Z, Chen EC, **Stahl M**, Zeidan AM. Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age. *Blood Rev*. 2023 May;59:101033. PMID: 36357283.
38. Rotter LK, Shimony S, Ling K, Chen E, Shallis RM, Zeidan AM, **Stahl M**. Epidemiology and Pathogenesis of Myelodysplastic Syndrome. *Cancer J*. 2023 May-Jun;29(3):111-121. PMID: 37195766.
39. Stempel JM, Xie Z, Bewersdorf JP, **Stahl M**, Zeidan AM. Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms. *Cancer J*. 2023 May-Jun;29(3):203-211. PMID: 37195777.
40. **Stahl M**, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski D, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore S, List AF, Kutchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa M, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultonwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. *Blood Adv*. 2023 Jun 27;7(12):2709-2714. PMID: 36260702, PMCID: PMC10333740.
41. Frumm SM, Shimony S, Stone RM, DeAngelo DJ, Bewersdorf JP, Zeidan AM, **Stahl M**. Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS. *Blood Rev*. 2023 Jul;60:101056. PMID: 36805300.
42. Bewersdorf JP, Xie Z, Bejar R, Borate U, Boultonwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, Porta MGD, DeZern AE, Fenaux P, Figueroa ME, Gore SD, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim TK, Komrokji R, Kuchroo VK, List AF, Loghavi S, Majeti R, Odenike O, Patnaik MM, Platzbecker U, Roboz GJ, Sallman DA, Santini V, Sanz G, Sekeres MA, **Stahl M**, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Xu ML, Savona MR, Wei AH, Zeidan AM. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). *Blood Rev*. 2023 Jul;60:101072. PMID: 36934059.
43. Santinelli E, Pascale MR, Xie Z, Badar T, **Stahl M**, Bewersdorf JP, Gurnari C, Zeidan AM. Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution. *Blood Rev*. 2023 Aug 29;101130. doi: 10.1016/j.blre.2023.101130. Epub ahead of print. PMID: 37679263.
44. Shallis RM, Daver N, Altman JK, Komrokji RS, Pollyea DA, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, **Stahl M**, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, Žučenka A, Zeidan AM. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. *Lancet Haematol*. 2023 Sep;10(9):e767-e776. PMID: 37572683.
45. **Stahl M**, Bewersdorf JP, Xie Z, Porta MGD, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, Sekeres MA, Sanz G, Sallman DA, Roboz GJ, Platzbecker U, Patnaik MM, Padron E, Odenike O, Nimer SD, Nazha A, Majeti R, Loghavi S, Little RF, List AF, Kim TK, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Gore SD, Greenberg P, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Daver NG, Churpek JE, Carraway HE, Buckstein R, Brunner AM, Boultonwood J, Borate U, Bejar R, Bennett JM, Wei AH, Santini V, Savona MR, Zeidan AM. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). *Blood Rev*. 2023 Aug 19;101128. PMID: 37704469.
46. Efficace F, Buckstein R, Abel GA, Giesinger JM, Fenaux P, Bewersdorf JP, Brunner AM, Bejar R, Borate U, DeZern AE, Greenberg P, Roboz GJ, Savona MR, Sparano F, Boultonwood J, Komrokji R, Sallman DA, Xie Z, Sanz G, Carraway HE, Taylor J, Nimer SD, Della Porta MG, Santini V, **Stahl M**, Platzbecker U, Sekeres MA, Zeidan AM. Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations

from the International Consortium for MDS (icMDS). *Hemasphere*. 2024 May 21;8(5):e69. doi: 10.1002/hem3.69. PMID: 38774655; PMCID: PMC11106800.

47. Alhajjah A, Bewersdorf JP, Bystrom RP, Zeidan AM, Shimony S, **Stahl M**. Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome. *Leuk Lymphoma*. 2024 Jul 4;1-11. doi: 10.1080/10428194.2024.2367040. Epub ahead of print. PMID: 38962996.
48. Carlson KS, Cunningham A, **Stahl M**, Winer E, Michaelis LC. Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems? *Acta Haematol*. 2024;147(2):122-132. doi: 10.1159/000535607. PMID: 38071966.

Peer-Reviewed Educational Materials

1. Santini V, **Stahl M**, Sallman DA. *TP53* Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates. *Am Soc Clin Oncol Educ Book*. 2024 Jun;44(3):e432650. doi: 10.1200/EDBK_432650. PMID: 38768424.

Peer-Reviewed Case Reports and Technical Notes

1. Suozzi KC*, **Stahl M***, Ko CJ, Chiang A, Gettinger SN, Siegel MD, Bunick CG. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. *JAAD Case Rep*. 2016 May;2(3):264-268. PMID: 27486590, PMCID: PMC4949498 (* co-first author).
2. **Stahl M**, Mohareb AM, Lee AI, Federman DG, Siddon AJ, Spelman J. Multi-system complications of hypereosinophilia. *Am J Hematol*. 2016 Jun;91(4):444-447. PMID: 26700720
3. **Stahl M**, Xu ML, Steensma DP, Rampal R, Much M, Zeidan AM. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. *Ann Hematol*. 2016 Jun;95(7):1197-1200. PMID: 27068405, PMCID: PMC7479634
4. Kim TK, Xu ML, Podoltsev NA, Prebet T, Barbarotta L, Amin K, Kasberg S, Roche K, **Stahl M**, Gore SD, Zeidan AM. Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. *Ann Hematol*. 2016 Oct;95(11):1895-1898. PMID: 27468851.
5. Weed J, Ko C, **Stahl M**, Much M, Witt D, Zeidan AM, Leventhal J. Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome. *Ann Hematol*. 2017 Jun;96(6):1037-1039. PMID: 28220192

Books

1. **Stahl M**, DeWolf S, Section Editors. Sections: Leukemia and Myelodysplastic Syndromes and Author AML and MDS; Myeloproliferative Neoplasms. In: *Pocket Oncology Third Edition*. Wolters Kluwer, 2022. ISBN/ISSN: 9781975190811.

Chapters

1. **Stahl M**, Tallman MS. Myelodysplastic syndromes. In: Leppert BC. *Netter's Integrated Review of Medicine*, 1st ed. Philadelphia, PA: Elsevier, 2021, p. 642-4.
2. **Stahl M**, Tallman MS. Myeloproliferative neoplasms. In: Leppert BC. *Netter's Integrated Review of Medicine*, 1st ed. Philadelphia, PA: Elsevier, 2021, p. 645-648.
3. **Stahl M**, Wieduwilt M. Section author Leukemia. In: 2022 edition of ASCO-SEP: Medical Oncology Self-Evaluation Program.
4. **Stahl M**, Wieduwilt M. Section author Leukemia. In: 2023 edition of ASCO-SEP: Medical Oncology Self-Evaluation Program.

Commentaries, Editorials, and Letters

1. **Stahl M**, Zeidan AM. Improved JAK Inhibition in Myelofibrosis-The Long Road Ahead. *JAMA Oncol*. 2018 May 1;4(5):659-660. PMID: 29522105.
2. **Stahl M**, Tallman MS. Antibody-based therapy in acute leukemia - beware the risks. *Leuk Lymphoma*. 2019 Jul;60(7):1608-1609. PMID: 31204877.
3. **Stahl M**, Tallman MS. Late and very late relapses in acute myeloid leukemia (AML). *Leuk Lymphoma*. 2020 May;61(5):1010-1011. PMID: 32283963.

4. **Stahl M**, Tallman MS. Outcomes of allogeneic stem cell transplantation for patients with t(6:9) AML- A strong case for allogeneic stem cell transplantation in first complete remission. *Br J Haematol*. 2020 Jun;189(5):806-808. PMID: 31999852.
5. **Stahl M**, Tallman MS, Goldberg AD. Measurable residual disease negativity in acute myeloid leukemia: the destination may matter more than the journey. *Leuk Lymphoma*. 2021 Sep;62(9):2050-2051. PMID: 34519611.
6. Bewersdorf JP, Stone RM, Tallman MS, **Stahl M**. Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?. *Leuk Lymphoma*. 2021 Dec;62(14):3318-3319. PMID: 34587866.
7. **Stahl M**, DeZern AE. Is there a path forward for immunotherapy in patients with myelodysplastic syndromes? *Lancet Haematol*. 2024 Jan;11(1):e5-e7. doi: 10.1016/S2352-3026(23)00343-5.